drugset
Drugs / Lu AA24493
last change Apr 2011 re-read 3 minutes ago

Lu AA24493

also known as CEPO

Protein / enzyme biologic

Developed for
ischemic stroke · Friedreich ataxia
Investigated by
H. Lundbeck A/S

Trials 3

today NCT01016366 · Ph 2 NCT00870844 · Ph 1 NCT00756249 · Ph 1
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT00870844 May 2009 → Dec 2010 ischemic stroke H. Lundbeck A/S Completed No outcome recorded
Phase 1 NCT00756249 Oct 2007 → Sep 2008 ischemic stroke H. Lundbeck A/S Completed No outcome recorded
Phase 21 trial
Phase 2 NCT01016366 Oct 2009 → Mar 2011 Friedreich ataxia H. Lundbeck A/S Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Lu AA24493 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01016366 ↗
2

NCT00870844 ↗

NCT00756249 ↗
Known as CEPO “Lu AA24493 (CEPO)” NCT00870844 ↗
Modality Protein / enzyme biologic “Lu AA24493 (CEPO) is a modified (carbamylated) version of EPO” NCT01016366 ↗
Route Intravenous “Vials with solution for i.v. injection.” NCT01016366 ↗